Beam Therapeutics Future Growth
Future criteria checks 0/6
Beam Therapeutics's revenue and earnings are forecast to decline at 30.9% and 14.4% per annum respectively. EPS is expected to decline by 12.5% per annum. Return on equity is forecast to be -105.5% in 3 years.
Key information
-14.4%
Earnings growth rate
-12.5%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | -30.9% |
| Future return on equity | -105.5% |
| Analyst coverage | Good |
| Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 57 | -492 | -333 | -314 | 5 |
| 12/31/2025 | 64 | -447 | -373 | -366 | 12 |
| 12/31/2024 | 63 | -452 | -366 | -356 | 14 |
| 12/31/2023 | 378 | -133 | -183 | -149 | N/A |
| 9/30/2023 | 82 | -285 | -392 | -353 | N/A |
| 6/30/2023 | 80 | -298 | -380 | -338 | N/A |
| 3/31/2023 | 77 | -287 | -353 | -306 | N/A |
| 12/31/2022 | 61 | -289 | -26 | 23 | N/A |
| 9/30/2022 | 92 | -315 | 39 | 94 | N/A |
| 6/30/2022 | 77 | -234 | 123 | 171 | N/A |
| 3/31/2022 | 60 | -238 | 148 | 191 | N/A |
| 12/31/2021 | 52 | -371 | -113 | -66 | N/A |
| 9/30/2021 | 1 | -401 | -134 | -92 | N/A |
| 6/30/2021 | 0 | -408 | -155 | -117 | N/A |
| 3/31/2021 | 0 | -366 | -132 | -107 | N/A |
| 12/31/2020 | 0 | -196 | -112 | -96 | N/A |
| 9/30/2020 | 0 | -132 | -100 | -89 | N/A |
| 6/30/2020 | 0 | -119 | -94 | -85 | N/A |
| 3/31/2020 | 0 | -106 | -87 | -74 | N/A |
| 12/31/2019 | 0 | -91 | -85 | -72 | N/A |
| 9/30/2019 | 0 | -86 | -79 | -57 | N/A |
| 6/30/2019 | 0 | -134 | -70 | -50 | N/A |
| 3/31/2019 | N/A | -124 | -57 | -42 | N/A |
| 12/31/2018 | N/A | -117 | -33 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BEAM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BEAM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BEAM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BEAM's revenue is expected to decline over the next 3 years (-30.9% per year).
High Growth Revenue: BEAM's revenue is forecast to decline over the next 3 years (-30.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BEAM is forecast to be unprofitable in 3 years.